MIR23B and benign neoplasm: Our results show that MIR23B mRNA expression was significantly lower in ovarian carcinomas and borderline tumors than in normal ovarian tissues and benign tumors, and the expression among age and pathological subtypes (mucinous vs. other types) was significantly different.